Efforts to reform federal drug pricing program 340B continue with new report, proposed CMS rule

Ongoing efforts to reform the federal 340B drug pricing program have advanced with the release of a new report and a proposed rule from the Centers for Medicare & Medicaid Services (CMS). These initiatives aim to address long-standing concerns regarding the program's oversight and the distribution of pharmaceutical discounts to eligible healthcare providers. For the pharmaceutical industry, these regulatory shifts are critical as they may redefine compliance requirements and financial interactions between manufacturers and covered entities.